<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Until recently, response assessment in patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was primarily performed by computed tomography (CT) </plain></SENT>
<SENT sid="1" pm="."><plain>Based on CT, International Workshop Criteria (IWC) were developed and widely used </plain></SENT>
<SENT sid="2" pm="."><plain>Fluorodeoxyglucose <z:chebi fb="4" ids="30225">Positron</z:chebi> Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> in <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and Revised Integrated International Workshop Criteria (IWC + PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques </plain></SENT>
<SENT sid="3" pm="."><plain>We determined whether these new IWC + PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), and therefore correlated IWC and IWC + PET response with time-to-next-treatment (TNT) in 69 patients with NHL </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrated that IWC + PET-guidelines are highly recommended over IWC-guidelines for patients with potentially-curable and routinely FDG-<z:chebi fb="156" ids="39214">avid</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, no additional value of IWC + PET was demonstrated in a small group of patients with incurable histological subtypes </plain></SENT>
</text></document>